Analgesic, Anesthetic and Addiction Clinical Trials Innovations, Opportunities, and Networks (ACTTION)

ACTTION public-private partnership (PPP) is a multi-year, multi-phase initiative that is aligned with the FDA's Critical Path Initiative. This ppp has been designed to streamline the discovery and development process for new analgesic, anesthetic, addiction, and peripheral neuropathy medications. The ppp is expected to develop innovative approaches in clinical trial designs to support regulatory decision making. The key objectives of ACTTION involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders — including academia, the FDA and other government agencies, industry, professional organizations, and patient advocacy groups — with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, such as scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency.